Compare Remitly Global Inc (RELY) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Remitly Global Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Remitly Global Inc trades at $23.5 (market cap $4.98B), while State Street SPDR S&P Biotech ETF trades at $149.93 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 2× Remitly Global Inc's market cap, and State Street SPDR S&P Biotech ETF is more actively traded (12,903,266 versus 3,501,150). Which is the better fit depends on your goals — on Pluang, investors hold Remitly Global Inc for 53 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| RELY | XBI | |
|---|---|---|
Market Cap | $4.98B | $10.11B |
Volume | 3,501,150 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $26.92 | $169.55 |
52-Week Low | $12.20 | $104.99 |
Typical Hold Time | 53 Days | 37 Days |
Enterprise Value | $4.34B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RELY trades at $22.93, down 1.16% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. Revenue has grown from $654M in 2022 to $1.64B in 2025, with net income turning positive at $67.93M. The company recently announced a partnership with Etsy and reported Q2 2026 revenue growth of 20% to $495M, with active customers surpassing 10 million.
The outlook is positive, supported by robust earnings beats, expanding margins, and a consensus analyst price target of $30.50 implying significant upside. Key risks include reliance on continued customer growth, competitive pressures in digital payments, and market volatility. Institutional ownership trends and insider sales warrant monitoring.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
